CY1111703T1 - Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους - Google Patents

Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους

Info

Publication number
CY1111703T1
CY1111703T1 CY20111100665T CY111100665T CY1111703T1 CY 1111703 T1 CY1111703 T1 CY 1111703T1 CY 20111100665 T CY20111100665 T CY 20111100665T CY 111100665 T CY111100665 T CY 111100665T CY 1111703 T1 CY1111703 T1 CY 1111703T1
Authority
CY
Cyprus
Prior art keywords
nucleotide sequences
invention refers
system components
present
component system
Prior art date
Application number
CY20111100665T
Other languages
English (en)
Original Assignee
Adienne S.R.L.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Adienne S.R.L. filed Critical Adienne S.R.L.
Publication of CY1111703T1 publication Critical patent/CY1111703T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Η παρούσα εφεύρεση αφορά ανασυνδυασμένα αντισώματα ανθρώπινης προέλευσης, ειδικά για το C5 συστατικό του ενεργοποιημένου συμπληρώματος, που χαρακτηρίζονται από την ικανότητα της αναστολής της μετατροπής της C5 άλφα αλυσίδας προς C5a και C5b. Επιπλέον, η παρούσα εφεύρεση αφορά τις νουκλεοτιδικές ακολουθίες και κωδικεύουν για τέτοια αντισώματα και τη θεραπευτική χρήση τόσο των πολυπεπτιδικών όσο και των νουκλεοτιδικών ακολουθιών, ιδιαίτερα για τη θεραπεία των νόσων που εμπλέκουν την καταστροφή του ιστού που προκύπτει από την ανεξέλεγκτη ενεργοποίηση του συστήματος συμπληρώματος.
CY20111100665T 2002-07-11 2011-07-08 Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους CY1111703T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT2002MI001527A ITMI20021527A1 (it) 2002-07-11 2002-07-11 Anticorpi anti componente c5 del complemento e loro uso
EP03763792A EP1529063B1 (en) 2002-07-11 2003-07-10 Antibodies anti-c5 component of the complement system and their use

Publications (1)

Publication Number Publication Date
CY1111703T1 true CY1111703T1 (el) 2015-10-07

Family

ID=30012505

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111100665T CY1111703T1 (el) 2002-07-11 2011-07-08 Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους

Country Status (12)

Country Link
US (3) US7999081B2 (el)
EP (1) EP1529063B1 (el)
AT (1) ATE506375T1 (el)
AU (1) AU2003246676A1 (el)
CY (1) CY1111703T1 (el)
DE (1) DE60336821D1 (el)
DK (1) DK1529063T3 (el)
ES (1) ES2365217T3 (el)
IT (1) ITMI20021527A1 (el)
PT (1) PT1529063E (el)
SI (1) SI1529063T1 (el)
WO (1) WO2004007553A1 (el)

Families Citing this family (67)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ITMI20021527A1 (it) * 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso
JP4755113B2 (ja) 2004-01-30 2011-08-24 クアーク・ファーマスーティカルス、インコーポレイテッド 線維性状態およびその他の疾患の治療のための、オリゴリボヌクレオチドおよびその使用方法
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2529746A1 (en) * 2005-06-06 2012-12-05 Girish J. Kotwal Methods for treatment or prophylaxis of reperfusion injury
US8168584B2 (en) 2005-10-08 2012-05-01 Potentia Pharmaceuticals, Inc. Methods of treating age-related macular degeneration by compstatin and analogs thereof
ME02886B (me) 2005-10-12 2018-04-20 Morphosys Ag Proizvodnja i karakterizacija potpuno humanih terapeutskih antitela dobijenih HuCAL GOLD tehnologijom, specifičnih za humani CD38
DK3056568T3 (da) 2006-03-31 2021-11-01 Chugai Pharmaceutical Co Ltd Fremgangsmåder til kontrollering af antistoffers blodfarmakokinetik
ES2530428T3 (es) * 2006-09-05 2015-03-02 Alexion Pharma Inc Métodos y composiciones para el tratamiento de neuropatías mediadas por anticuerpos
GB0617734D0 (en) * 2006-09-08 2006-10-18 Evolutec Ltd Method of treating peripheral nerve disorders
EP2067043B1 (en) * 2006-09-08 2013-07-17 University of Oxford Clinical diagnosis of hepatic fibrosis using inter-alpha-trypsin inhibitor heavy chain h4
EP2148691B1 (en) 2007-02-05 2015-05-20 Apellis Pharmaceuticals, Inc. Compstatin analogues for use in the treatment of inflammatory conditions of the respiratory system
JP5334319B2 (ja) 2007-09-26 2013-11-06 中外製薬株式会社 Ｃｄｒのアミノ酸置換により抗体の等電点を改変する方法
EP3521311A1 (en) 2008-04-11 2019-08-07 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
AU2014201433B2 (en) * 2008-08-05 2016-05-26 Novartis Ag Compositions and methods for antibodies targeting complement protein C5
AR072897A1 (es) * 2008-08-05 2010-09-29 Novartis Ag Composiciones y metodos para anticuerpos que se dirigen a la proteina de complemento c5
AU2009322145A1 (en) 2008-12-05 2011-06-23 Abraxis Bioscience, Llc SPARC Binding ScFvs
US8889364B2 (en) * 2009-05-14 2014-11-18 The Chancellor, Masters And Scholars Of The University Of Oxford Clinical diagnosis of hepatic fibrosis using a novel panel of low abundant human plasma protein biomarkers
RU2642318C2 (ru) 2010-11-30 2018-01-24 Чугаи Сейяку Кабусики Кайся Антигенсвязывающая молекула, способная многократно связываться с множеством антигенных молекул
EP2468295A1 (en) * 2010-12-21 2012-06-27 Affiris AG Vaccines based on peptides of the complement protein C5a
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
CN103796667A (zh) 2011-06-22 2014-05-14 艾普莱斯制药公司 用补体抑制剂治疗慢性障碍的方法
WO2013047748A1 (ja) 2011-09-30 2013-04-04 中外製薬株式会社 複数の生理活性を有する抗原の消失を促進する抗原結合分子
EP3517550A1 (en) 2011-11-30 2019-07-31 Chugai Seiyaku Kabushiki Kaisha Drug containing carrier into cell for forming immune complex
AU2012356170B2 (en) 2011-12-21 2016-06-16 Novartis Ag Compositions and methods for antibodies targeting Factor P
WO2013126006A1 (en) 2012-02-20 2013-08-29 Swedish Orphan Biovitrum Ab (Publ) Polypeptides binding to human complement c5
KR102273985B1 (ko) 2012-08-24 2021-07-06 추가이 세이야쿠 가부시키가이샤 ＦｃγＲＩＩｂ 특이적 Ｆｃ영역 개변체
BR112015006581A2 (pt) 2012-09-27 2017-07-04 Octapharma Ag teste para potencial hemolítico de produtos e formulações farmacêuticos para minimização de risco
CA2891673A1 (en) 2012-11-15 2014-05-22 Apellis Pharmaceuticals, Inc. Cell-reactive, long-acting, or targeted compstatin analogs and related compositions and methods
WO2014152391A1 (en) 2013-03-15 2014-09-25 Apellis Pharmaceuticals, Inc. Cell-penetrating compstatin analogs and uses thereof
ES2514165B1 (es) * 2013-03-27 2015-09-09 Consejo Superior De Investigaciones Científicas (Csic) Anticuerpo anti-factor b, composición farmacéutica útil para el tratamiento de enfermedades del complemento y sus aplicaciones
WO2014160958A1 (en) 2013-03-29 2014-10-02 Alexion Pharmaceuticals, Inc. Compositions and methods for increasing the serum half-life of a therapeutic agent targeting complement c5
MX2015014017A (es) 2013-04-02 2016-02-10 Chugai Pharmaceutical Co Ltd Variante de la region fc.
US10254288B2 (en) * 2013-08-16 2019-04-09 Quidel Corporation Method for species-independent measurement of complement activation in animals
LT3039033T (lt) 2013-08-28 2019-10-25 Affibody Ab Surišantys polipeptidai, turintys mutuotą karkasą
NZ718153A (en) 2013-08-28 2022-05-27 Ipc Res Llc Stable polypeptides binding to human complement c5
US10238700B2 (en) 2014-01-02 2019-03-26 Genelux Corporation Oncolytic virus adjunct therapy with agents that increase virus infectivity
WO2016081314A1 (en) 2014-11-17 2016-05-26 Alexion Pharmaceuticals, Inc. Risk evaluation and management strategy involving patient follow-ups relating to a complement inhibitor
US20160168237A1 (en) 2014-12-12 2016-06-16 Alexion Pharmaceuticals, Inc. Method for treating a complement mediated disorder caused by an infectious agent in a patient
LT3233921T (lt) 2014-12-19 2021-12-10 Chugai Seiyaku Kabushiki Kaisha Anti-c5 antikūnai ir panaudojimo būdai
WO2016117346A1 (en) 2015-01-22 2016-07-28 Chugai Seiyaku Kabushiki Kaisha A combination of two or more anti-c5 antibodies and methods of use
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
EP3359566A1 (en) 2015-10-07 2018-08-15 Alexion Pharmaceuticals, Inc. A method for treating age-related macular degeneration in a patient
EP4349363A3 (en) 2015-10-07 2024-06-19 Apellis Pharmaceuticals, Inc. Dosing regimens
JP6390647B2 (ja) * 2016-03-10 2018-09-19 株式会社豊田自動織機 永久磁石式回転電機
KR20240070728A (ko) 2016-06-14 2024-05-21 리제너론 파아마슈티컬스, 인크. 항-c5 항체 및 이의 용도
TWI693940B (zh) 2016-08-05 2020-05-21 日商中外製藥股份有限公司 Ｉｌ-８相關疾病之治療用或預防用組成物
EP3529618B1 (en) 2016-10-19 2020-12-02 Alexion Pharmaceuticals, Inc. A method of quantitating unbound c5 in a sample
US20190367599A1 (en) 2017-01-31 2019-12-05 Chugai Seiyaku Kabushiki Kaisha Pharmaceutical composition for use in the treatment or prevention of a c5-related disease and a method for treating or preventing a c5-related disease
IL303696A (en) 2017-03-01 2023-08-01 Achillion Pharmaceuticals Inc Aryl, heteroaryl and heterocyclic pharmaceutical compounds for the treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
EP3606465A4 (en) 2017-04-07 2021-03-24 Apellis Pharmaceuticals, Inc. DOSING PLANS, ASSOCIATED COMPOSITIONS AND PROCEDURES
WO2019118556A1 (en) 2017-12-13 2019-06-20 Regeneron Pharmaceuticals, Inc. Anti-c5 antibody combinations and uses thereof
BR112021001655A2 (pt) 2018-08-01 2021-05-04 Chugai Seiyaku Kabushiki Kaisha composição farmacêutica para uso no tratamento ou prevenção de uma doença relacionada a c5 e método para tratar ou prevenir uma doença relacionada a c5
EP3841086A4 (en) 2018-08-20 2022-07-27 Achillion Pharmaceuticals, Inc. PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF MEDICAL DISORDERS RELATED TO COMPLEMENT FACTOR D
EP3846803A4 (en) 2018-09-06 2022-08-10 Achillion Pharmaceuticals, Inc. MACROCYCLIC COMPOUNDS FOR THE TREATMENT OF MEDICAL DISORDERS
MX2021002640A (es) 2018-09-06 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
MX2021003425A (es) 2018-09-25 2021-07-16 Achillion Pharmaceuticals Inc Formas morficas de los inhibidores del factor d del complemento.
KR20240001329A (ko) 2019-07-31 2024-01-03 에프. 호프만-라 로슈 아게 항-c5 항체 크로발리맙의 사용에 의한 c5-관련 질병의 치료 또는 예방을 위한 투여량 및 투여 섭생
JP7437261B2 (ja) 2019-07-31 2024-02-22 エフ・ホフマン－ラ・ロシュ・アクチェンゲゼルシャフト 抗ｃ５抗体クロバリマブの使用によるｃ５関連疾患の治療または予防のための薬用量および投与レジメン
JP2022544589A (ja) 2019-08-16 2022-10-19 リジェネロン・ファーマシューティカルズ・インコーポレイテッド 高濃度抗ｃ５製剤
JP2023503776A (ja) 2019-09-27 2023-02-01 ヴォリューション イミュノ ファーマシューティカルズ エスエイ 造血幹細胞移植後の血栓性微小血管症（ｈｓｃｔ－ｔｍａ）の治療方法
WO2021067526A1 (en) 2019-10-02 2021-04-08 Alexion Pharmaceuticals, Inc. Complement inhibitors for treating drug-induced complement-mediated response
CN115052889A (zh) 2019-10-25 2022-09-13 瑞泽恩制药公司 用于治疗或预防c5相关疾病的给药方案
JP2023522208A (ja) 2020-04-16 2023-05-29 アシスタンス ピュブリック－オピト ド パリ ウイルスによって引き起こされる補体媒介性障害を処置する方法
EP4150338A1 (en) 2020-05-15 2023-03-22 Alexion Pharmaceuticals, Inc. Method of using extracellular vesicles to detect complement activation, and uses thereof to assess and/or monitor treatment of a complement-mediated disease
CN118251491A (zh) 2021-10-28 2024-06-25 瑞泽恩制药公司 用于敲除C5的CRISPR/Cas相关方法及组合物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5770429A (en) * 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6074642A (en) * 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
EP3031827A1 (en) * 2000-10-10 2016-06-15 Genentech, Inc. Inhibition of complement c5 activation for the treatment and prevention of delayed xenograft or acute vascular rejection
US20040001822A1 (en) * 2000-12-29 2004-01-01 Avigdor Levanon Y1-isolated molecules comprising epitopes containing sulfated moieties, antibodies to such epitopes, and uses thereof
US6881557B2 (en) * 2001-07-12 2005-04-19 Arrowsmith Technologies Llp Super humanized antibodies
ITMI20021527A1 (it) 2002-07-11 2004-01-12 Consiglio Nazionale Ricerche Anticorpi anti componente c5 del complemento e loro uso

Also Published As

Publication number Publication date
ITMI20021527A1 (it) 2004-01-12
WO2004007553A8 (en) 2004-04-29
AU2003246676A1 (en) 2004-02-02
DE60336821D1 (de) 2011-06-01
US7999081B2 (en) 2011-08-16
WO2004007553A1 (en) 2004-01-22
ES2365217T3 (es) 2011-09-26
US20130071922A1 (en) 2013-03-21
US8282929B2 (en) 2012-10-09
US8962819B2 (en) 2015-02-24
SI1529063T1 (sl) 2011-08-31
DK1529063T3 (da) 2011-06-20
PT1529063E (pt) 2011-07-25
AU2003246676A8 (en) 2004-02-02
US20060115476A1 (en) 2006-06-01
US20120009184A1 (en) 2012-01-12
EP1529063B1 (en) 2011-04-20
ATE506375T1 (de) 2011-05-15
EP1529063A1 (en) 2005-05-11

Similar Documents

Publication Publication Date Title
CY1111703T1 (el) Αντισωματα του αντι-c5 συστατικου του συστηματος συμπληρωματος και η χρηση τους
GEP20115324B (en) Tweak binding antibodies
IS8432A (is) Mótefni sem bindast viðtaka hvítfrumuboða-4
AR083740A1 (es) Anticuerpos dkk1 (dickkopf-1) y metodos de uso
MX338122B (es) Epitopes terapeuticos y usos de los mismos.
ATE552849T1 (de) Behandlungsverfahren unter verwendung von ctla-4 antikörpern
PE20091193A1 (es) Proteinas humanas de union a antigenos del gm-csf
DK1809321T3 (da) Adoptiv immunterapi med forøget T-lymfocytoverlevelse
MXPA06012601A (es) Anticuerpos especificos de fcy riib humanizados y metodos de uso de los mismos.
DK1534335T3 (da) FcgammaRIIB-specifikke antistoffer og fremgangsmåder til anvendelse deraf
MX2007013626A (es) Anticuerpos dirigidos contra el peptido beta amiloide y procedimientos que usan los mismos.
UA99094C2 (ru) Способ лечения пациента с системной красной волчанкой
SG158089A1 (en) Antiangiogenesis therapy of autoimmune disease in patients who have failed prior therapy
TW200606177A (en) Glycoprotein VI antibodies and methods thereof
EA201070636A1 (ru) Ингибирование рецептора белка, стимулирующего макрофаги (ron), и способы его лечения
WO2009154995A3 (en) Interleukin 10 receptor (il-10r) antibodies and methods of use
UA87128C2 (ru) ИММУНОГЛОБУЛИН АНТИ-EрCAM И СПОСОБ ЕГО ВВЕДЕНИЯ ДЛЯ ЛЕЧЕНИЯ ОНКОЛОГИЧЕСКИХ ЗАБОЛЕВАНИЙ
CL2023001836A1 (es) Tratamiento de glomerulopatía c3 usando un inhibidor de c5a
ATE525401T1 (de) Vom tumorantigen 5t4 abgeleitete mhc-klasse-i- und ii-peptidantigene
ATE482976T1 (de) Defensinproteine
NO20052525D0 (no) Spleisevariant av humant hypofyseveksthormon
IL174134A0 (en) Use of a protein in the preparation of a medicament for treatment of fibrotic diseases
AU2013204942B2 (en) Epitopes related to coeliac disease
TH139454A (th) การใช้แหล่ง l3และ/หรือ l5 ในฐานะเป็นวัคซีน หรือในเชิงวินิจฉัยสำหรับโรคปรสิต
RU2019127190A (ru) Антитела против cxcr4